Key facts
- This page summarizes Stephen J. Tulipano's Form 4 filing for Stoke Therapeutics, Inc. (STOK).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 07 Jun 2024, 16:35.
Stephen J. Tulipano - 27 Mar 2024 Form 4 Insider Report for Stoke Therapeutics, Inc. (STOK)
- Reporting relationship
- Former CFO
- Issuer ticker
- STOK
- Reported as of
- 27 Mar 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 07 Jun 2024, 16:35:10 UTC
- Prior SEC filing
- 19 Mar 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Stephen Tulipano
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Stephen J. Tulipano filed Form 4 for Stoke Therapeutics, Inc. (STOK) on 07 Jun 2024.
Change
- Previous filing in this sequence was filed on 19 Mar 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
STOK
transaction
Derivative
Employee Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +60,000
- Change %
- Price
- $0.000000
- Shares after
- 60,000
- Date
- 27 Mar 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 60,000
- Exercise price
- $14.17
- Footnotes
- F1
STOK
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +40,000
- Change %
- Price
- $0.000000
- Shares after
- 40,000
- Date
- 27 Mar 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 40,000
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The option vested or vests as to 1/48 of the total award on April 15, 2024, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date.
Footnote F2
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement.
Footnote F3
The award vests as to 1/4 of the total award annually beginning on March 15, 2025, subject to the reporting person's continued service to the issuer through each vesting date.